Edwards Lifesciences reported strong financial results for the fourth quarter and full-year ended December 31, 2024. Fourth-quarter TAVR sales reached $1.04 billion, growing 6% (5% constant currency), contributing to full-year 2024 global TAVR sales of $4.1 billion, up 6% year-over-year.
The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment continued its rapid expansion, with fourth-quarter sales of $105 million and full-year sales of $352 million, representing a 78% increase year-over-year. Surgical sales from continuing operations grew 6% (5% constant currency) to $244 million in the fourth quarter, driven by the RESILIA portfolio.
The company reported an adjusted gross profit margin of 79.0% for the quarter and adjusted earnings per share of $0.59. Edwards maintained its full-year 2025 total company and product group sales guidance, as well as its adjusted EPS guidance of $2.40 to $2.50. For the first quarter of 2025, the company projects total sales between $1.35 billion and $1.43 billion and adjusted EPS of $0.58 to $0.64.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.